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1.0 Introduction 
HIV is an important public health issue, and warrants prioritisation for surveillance. Accurate 
and complete surveillance information on new HIV diagnoses is essential, in order to 
monitor the epidemiology of HIV over time, and evaluate the effect of prevention strategies 
and interventions. 
 
This report describes the completeness of the HIV enhanced surveillance system in Ireland 
over a two year period from January 1st 2012 to December 31st 2013. It is the first report to 
examine the completeness of HIV reporting since it became a notifiable disease in Ireland, 
and was included in the national Computerised Infectious Disease Reporting System, CIDR.  
 
Data were extracted from CIDR on 23rd July 2014 and were correct at the time of 
publication. 
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2.0 Background 
HIV was made a notifiable disease in Ireland in September 2011. Since January 2012 
onwards, all newly confirmed cases of HIV are notified via CIDR. CIDR is Ireland’s secure 
national web-based electronic reporting system that can only be accessed through the 
Government VPN.  
 
 
2.1 HIV surveillance system 
All HIV positive cases detected in laboratories in Ireland are confirmed in the National Virus 
Reference Laboratory (NVRL).  The NVRL’s case definition for HIV requires confirmation of 
HIV on a second sample (serology or HIV viral load >200 copies per ml) prior to notification 
for surveillance (Appendix 1). NVRL also reviews its in-house database to determine that this 
person is newly diagnosed.   
 
On confirmation with the second sample, the NVRL enters the case into CIDR, and it is sent 
securely within CIDR to the Department of Public Health in the area where the clinician who 
requested the test is based. If the HIV sample has come to the NVRL from a laboratory, the 
result on CIDR is sent to Public Health via the laboratory. Public Health then creates an 
event of HIV on CIDR, and epidemiological reports are based on these HIV events.  
 
The NVRL also sends an enhanced surveillance form to the clinician who requested the 
confirmatory HIV test. The clinician completes the form and returns it to the relevant 
Department of Public Health who update the HIV event on CIDR with the enhanced data 
received. In situations where a completed form is not received by Departments, or where a 
submitted form is very incomplete, Department personnel actively liaise with the relevant 
clinicians to facilitate provision of the required surveillance data. The current HIV 
surveillance form is shown in Appendix 2.  
 
Anonymised data are analysed at a national level by HPSC. With the use of CIDR, HIV data 
can now be analysed in real time and are included in the weekly HPSC infectious disease (ID) 
report and the weekly HIV&STI report (see 
http://www.hpsc.ie/hpsc/NotifiableDiseases/WeeklyIDReports/).  
 
 
2.2 HIV Paediatric reporting 
In relation to newly diagnosed paediatric HIV cases, a separate process for notification is 
undertaken. All paediatric cases are referred for management to Dr Karina Butler, 
Consultant Physician in Paediatric Infectious Diseases, Our Lady’s Children’s Hospital, 
Crumlin.  A surveillance form on each confirmed paediatric HIV infection is sent to the 
British Paediatric Surveillance Unit (BPSU) in the United Kingdom (UK), and a copy of each 
form is sent to the relevant Department of Public Health in Ireland. Public Health then 
creates a new clinical notification of HIV and enters the relevant enhanced information into 
CIDR. A copy of the BPSU HIV paediatric form can be seen at  
http://www.ucl.ac.uk/nshpc/documents/forms/blue-form-color.pdf  
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3.0 Return of HIV surveillance report forms 
 
Between January 1st 2012 and December 31th 2013, 674 adult cases of HIV were newly 
confirmed by the NVRL and an enhanced surveillance form on each case was sent to the 
clinician who requested the confirmatory HIV test.  
 
Table 1 below provides a breakdown of forms which were sent by NVRL to clinicians by the 
HSE area where the clinicians are based. This table is based on a variable in CIDR called 
“Primary Lab Referral Source” which is completed by the NVRL and represents the 
clinician/clinic who requested the confirmatory HIV test. The majority of forms were sent to 
clinicians in HSE-East while the least were sent to HSE-Northwest.  
 
 
Table 1: Forms sent to clinicians by HSE area of clinician (2012 and 2013) 
 
HSE Area 
2012 2013 Total 
Number % Number % Number  % 
East 273 81.5 254 74.9 527 78.2 
Midlands 5 1.5 3 0.9 8 1.2 
Midwest 18 5.4 22 6.5 40 5.9 
Northeast 3 0.9 5 1.5 8 1.2 
Northwest 1 0.3 2 0.6 3 0.4 
South 21 6.3 33 9.7 54 8.0 
Southeast 6 1.8 10 2.9 16 2.4 
West 8 2.4 10 2.9 18 2.7 
Total 335 100.0 339 100.0 674 100.0 
 
A further eight paediatric cases were notified by the Rainbow Clinic directly to Departments 
of Public Health in 2012 and 2013 (five in 2012 and three in 2013) and were entered onto 
CIDR as clinical notifications.  
Table 2 provides a breakdown of the forms returned by year. In 2012, 89% of enhanced 
forms were returned while in 2013, 93% of enhanced forms were returned. 
 
Table 3 provides a detailed breakdown of form returns for each HSE area, plus each 
Hospital/G.P./Clinic in that area (based on the field “Primary Lab Referral Source” in CIDR). 
The percentage of forms returned by HSE areas ranged from 75-100%.  
 
Table 2: Enhanced forms completed and returned (2012 and 2013) 
Enhanced form returned 2012 2013 Total 
 No. % No. % No. % 
Yes 299 89.3 315 92.9 614 91.1 
No 36 10.7 24 7.1 60 8.9 
Total 335 100.0 339 100.0 674 100.0 
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Table 3: Return of enhanced surveillance form by HSE area and by hospital/G.P./Clinic1  
 
 
                                                          
1
 This table reflects the area/hospital of the clinician/clinic which has requested the confirmatory HIV test – the 
“primary lab referral source” in CIDR.  
Area Hospital/Clinic/GP Number 
of forms 
sent 
Number 
of forms 
returned 
% of 
forms 
returned 
HSE East Baggot Street Clinic 2 2 100.0 
Beaumont Hospital 62 60 96.8 
Catherine McAuley Clinic 15 8 53.3 
Connolly Hospital 3 1 33.3 
Coombe Women's Hospital 2 1 50.0 
Gay Men's Health Clinic 14 12 85.7 
Mater Hospital 91 74 81.3 
Naas General Hospital 2 2 100.0 
National Maternity Hospital, Holles St 2 2 100.0 
Rotunda Hospital 14 13 92.9 
St. James's (incl. GUIDE) 259 254 98.1 
St. Vincent's Hospital 11 6 54.5 
Tallaght Hospital  6 3 50.0 
G.P.'s/Clinics 44 36 81.8 
Total 527 474 89.9 
Midlands Midlands Regional Hospital,  Mullingar 4 4 100.0 
Midlands Regional Hospital, Portlaoise 1 1 100.0 
Midlands Regional Hospital, Tullamore 3 3 100.0 
Total 8 8 100.0 
Midwest Midwestern Regional Hospital, Limerick 40 38 95.0 
Total 40 38 95.0 
Northeast Cavan General Hospital 1 0 0.0 
Our Lady of Lourdes Hospital, Drogheda 4 3 75.0 
Our Lady's Hospital, Navan 3 3 100.0 
Total 8 6 75.0 
Northwest GP 1 1 100.0 
Letterkenny General Hospital - GUM 1 1 100.0 
Sligo General Hospital 1 1 100.0 
Total 3 3 100.0 
Southeast St Luke's Kilkenny 2 2 100.0 
GPs 6 6 100.0 
Waterford Regional Hospital 7 7 100.0 
Wexford General Hospital 1 1 100.0 
Total 16 16 100.0 
West Galway University Hospital 18 17 94.4 
Total 18 17 94.4 
South Bon Secours Hospital, Cork 2 2 100.0 
Bon Secours Hospital, Tralee 1 1 100.0 
Cork University Hospital 21 20 95.2 
GPs/Clinics 20 19 95.0 
Mercy Hospital 2 2 100.0 
STI Clinic, Victoria Hospital 4 4 100.0 
Tralee General Hospital 4 4 100.0 
Total 54 52 96.3 
Ireland Total 674 614 91.1 
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4.0 Completeness of HIV data  
The completeness of data items on CIDR are detailed in table 4. Some of the data items (i.e. 
DOB, gender) are provided by the NVRL and/or source laboratory in the initial notification to 
Public Health. Most of the remaining data items are then provided by clinicians on the HIV 
enhanced surveillance form. However, the NVRL also provide additional information in CIDR, 
where available, including probable route of transmission, date of last negative test, result 
of P24 antigen test and HIV type. Because data items can be completed from clinical and/or 
laboratory data, the percentage complete is reported as a percentage of total cases. 
Appendix 3 describes the completeness of the data in cases where enhanced forms were 
returned.  
 
Data on county reflects the county of residence of the patient, if address information is 
available. If address information is not available, the county will reflect the county of the 
laboratory or the county of the treating clinician.  
 
There was huge variation in the completeness of individual variables ranging from 21-100%. 
Overall data completeness for key fields for HIV surveillance during this time period was 
good. Probable route of transmission was provided for more than 90% of cases in both 2012 
and 2013. An improvement in data completeness between 2012 and 2013 was noted for 
CD4 count at diagnoses (from 80% to 89%), country of birth (from 86% to 92%) and 
probable country of infection (from 66% to 71%).  
 
Overall data completeness for some fields was low, namely, previously tested negative for 
HIV (64% in 2013), duration of drug use if drug user (44% in 2013), stage of hepatitis B 
infection if co-infected with hepatitis B (44% in 2013), gestational age if pregnant (43% in 
2013) and stage of hepatitis C infection if co-infected with hepatitis C (21% in 2013).  
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Table 4: Completeness of HIV data items, 2012 and 2013 (cells with less than 80% are 
highlighted in red) 
Section Question % complete 
in 2012 
% complete 
in 2013 
Patient Details DOB 100.0 100.0 
Sex 100.0 100.0 
County of residence 100.0 100.0 
Date of diagnosis 99.4 100.0 
Country of Birth 86.2 92.1 
Ethnicity 72.9 76.3 
Probable Country of Infection 66.2 71.9 
Sexual Orientation 89.7 91.5 
Pregnant (% of females) 81.4 76.7 
Gestational age (% of those pregnant) 76.2 42.9 
Reason for test 81.8 84.8 
Probable route of HIV 
infection 
Probable route of transmission 94.4 92.7 
> Hetero subcategory (% of hetero cases) 81.2 75.9 
> Mother to Child subcategory (% of MTCT cases) 100.0 100.0 
> Duration of drug use (% of IDUs) 69.2 44.4 
Laboratory 
information 
CD4 count at diagnosis 80.0 88.9 
CD4 % at diagnosis 67.4 71.3 
Viral load at diagnosis 71.5 77.2 
Date of initial NVRL test 87.1 88.3 
HIV type 99.1 99.4 
P24 antigen
1
 na na 
Testing history Previously tested positive for HIV  75.9 78.7 
> Country of test (% of those who tested positive 
previously) 
92.8 93.5 
> Year of test (% of those who tested positive previously) 85.5 87.1 
Previously tested negative for HIV 62.6 63.5 
> Country of test (% of those who tested negative 
previously) 
91.8 90.0 
> Year of test (% of these who tested negative previously) 95.1 90.8 
Co-infections Co-infected with syphilis 82.4 87.4 
Co-infected with chlamydia 79.4 85.1 
Co-infected with gonorrhoea 79.7 85.4 
Co-infected with hepatitis B 82.6 90.9 
Co-Infected with hepatitis C 83.2 88.3 
> Stage of hepatitis B infection (% of those with hep B) 58.8 44.4 
> Stage of hepatitis C infection (% of those with hep C) 23.1 20.7 
Clinical Stage and 
AIDS 
Clinical Stage  87.1 85.4 
> Date of AIDS diagnosis (% of those with AIDS defining 
illness) 
82.4 78.6 
> AIDS-defining illness (% of those with AIDS defining 
illness) 
97.1 96.4 
ART indicated 63.8 71.9 
ART initiated 60.6 71.3 
> Date ART initiated (% of those with ART initiated) 87.2 87.6 
1
P24 antigen test is not carried out on all new diagnoses therefore is not given as a percentage of total cases 
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4.1  Mother-to-Child transmission 
For cases where the route of transmission is reported as mother-to-child, an additional six 
data items are collected. The questions relate to the source of maternal infection, timing of 
the mothers diagnosis (before, during or after birth) and whether the mother and/or baby 
received anti-retroviral therapy (before/during or after birth).  
 
Eight cases where the probable route of transmission was mother-to-child were notified in 
2012 and 2013 (5 in 2012 and 3 in 2013). Data completeness for the additional items ranged 
from 38-100% (see table 5). However, it is important to note that all of the MTCT cases 
diagnosed in 2012 and 2013 were born in sub-Saharan Africa and therefore clinical 
information relating to their birth may not be readily available.  
 
 
Table 5: Completeness of HIV enhanced questions – MTCT, 2012 and 2013 data 
Item Number 
complete 
% complete of 
MTCT cases 
Subcategory of Mother 8 100.0 
Timing of HIV diagnosis 3 37.5 
ART for Mother/Baby 3 37.5 
ART given ante-natally 4 50.0 
ART given intra-partum 4 50.0 
ART given post-partum 3 37.5 
 
 
4.2 Acute/Sero-conversion illness  
From January 1st 2012, it was agreed with surveillance partners to gather additional 
information relating to contact tracing and sexual networks for cases where the clinician has 
indicated that the stage of infection is “acute, sero-conversion illness”.  
 
There were 27 cases in 2012 and 2013, where the clinician indicated that the infection was 
an “acute, sero-conversion illness”. Table 6 describes the completeness of additional data 
collected for these cases.  
 
Table 6: Completeness of HIV enhanced questions – Acute/Sero-conversion cases, 2012 
and 2013 cases 
Item  Number 
complete 
% 
complete 
Has contact tracing taken place 9 33.3 
Number of sexual contacts in the last 3 months - total  
(of those where contact tracing took place) 
6 66.7 
Any social/sexual networks identified?  9 33.3 
If network identified, has public health been informed? (none identified) na na 
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4.3 Completeness by HSE area 
Table 7 describes the completeness of key surveillance variables by HSE area for 2012 and 
2013.   
 
Table 7: Completeness of key surveillance variables by HSE area, 2012 and 2013 data 
 % Complete in 2012  
HSE Area Probable 
route of 
transmission 
CD4 count Country 
of birth 
Probable 
county of 
infection  
Clinical 
Stage 
Total 
cases 
2012 
East 94.6 82.6 86.0 73.6 88.0 242 
Midlands 90.0 80.0 100.0 80.0 100.0 10 
Midwest 95.0 90.0 95.0 55.0 75.0 20 
Northeast 94.1 52.9 64.7 52.9 64.7 17 
Northwest 100.0 83.3 83.3 50.0 100.0 6 
Southeast 100.0 78.6 100.0 78.6 100.0 14 
South 90.5 61.9 85.7 14.3 90.5 21 
West 90.0 80.0 80.0 20.0 80.0 10 
Total 94.4 80.0 86.2 66.2 87.1 340 
 
 % Complete in 2013  
HSE Area Probable 
route of 
transmission 
CD4 count Country 
of birth 
Probable 
county of 
infection  
Clinical 
Stage 
Total 
cases 
2013 
East 92.8 91.9 91.1 75.3 86.0 235 
Midlands 90.0 80.0 100.0 100.0 100.0 10 
Midwest 90.9 81.8 95.5 54.5 77.3 22 
Northeast 92.9 85.7 100.0 50.0 78.6 14 
Northwest 80.0 100.0 100.0 100.0 100.0 5 
Southeast 91.7 75.0 66.7 66.7 91.7 12 
South 93.9 81.8 100.0 66.7 78.8 33 
West 100.0 81.8 90.9 45.5 90.9 11 
Total 92.7 88.9 92.1 71.9 85.4 342 
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7B5 .0  Discussion 
 
HIV enhanced surveillance in Ireland involves collaboration with many partners and requires 
significant commitment and effort by all to ensure the quality and usefulness of the data.  
The purpose of this report is to review and report on the completeness and quality of the 
first two years of HIV surveillance data in CIDR.  
 
Of the new HIV infections diagnosed in 2012 and 2013, 89% and 93% respectively of HIV 
enhanced surveillance forms were completed by clinicians and returned to Public Health (as 
of 23rd July 2014). This is similar to the percentages returned in recent years; 86% in 2011 
and 89% in 2010. While the review highlighted excellent rate of returns from many 
clinics/locations, the evaluation also identified some areas where improvements in 
surveillance are needed.  
 
It is important to obtain data on key variables for all new HIV diagnoses in order to monitor 
the spread of the HIV epidemic in Ireland. In addition to return of forms, Public Health have 
actively sought information from clinicians on key surveillance variables and data 
completeness for these variables such as probable route of transmission and CD4 count was 
greater than 90% and 80% respectively during this time period, indicating good quality 
surveillance. Comparing to a European perspective, data on probable route of transmission 
is available for 88% of new diagnoses and CD4 count at diagnosis for 55% of new diagnoses 
in European Union/European Economic Area (EU/EEA) countries in 2012.1 
 
Some of the data items have not been included in national HIV reports and are not required 
for reporting to ECDC, namely sexual orientation, country of previous negative test and 
CD4%. From January 2015 onwards, it is proposed to remove these three data items from 
the HIV surveillance form.  The usefulness and value of other data items on the HIV 
surveillance form will also be considered following the outcome of an EPIET project which is 
commencing in autumn 2014 and will evaluate HIV surveillance in Ireland. The usefulness 
and value of the additional data items collected on acute cases only will also be reviewed 
following the evaluation and once the results of the planned Recent Infection Testing 
Project are available. It is proposed that some additional data items, including date of CD4 
test, date of viral load test, ART history and year of arrival in Ireland will be added to the HIV 
surveillance report form from January 2015 onwards.   
 
Currently, anonymised HIV data are reported to ECDC annually and 31 data items are 
included in the dataset provided. HIV surveillance in Europe is currently under review, and 
ECDC has commissioned Public Health England to work with them to develop a new 
integrated HIV and AIDS dataset. The revised dataset consists of 34 fields which relate to 
patient demographics, clinical markers and death. The objectives of the revised dataset are 
to 
 Integrate HIV and AIDS surveillance into a single data return 
 Expand the focus of HIV surveillance to the monitoring of all those living with HIV 
(not just new diagnoses) 
 Simplify reporting of HIV exposure 
 Improve the quality and clarity of data relating to migrants  
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 Include additional biomedical markers such as viral load and recent infection 
 Monitor the extent that patients diagnosed with HIV are linked into HIV care, treated 
and obtain an undetectable viral load (the “continuum of care”).   
 
While not all countries can provide all the items in the new dataset, the aim is that over the 
medium-term, increasing numbers of countries will be able to design and enhance national 
surveillance systems so that they can provide the full set of variables in the future. In order 
to assess the feasibility of collecting the additional variables, the revised dataset has been 
piloted across EU member states and Ireland was part of this pilot. A report on the pilot will 
be produced and circulated in the coming months. A copy of the current dataset provided to 
ECDC and the proposed dataset can be seen in Appendix 4.  
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Appendix 1: Working case definition for HIV surveillance (NVRL)  
 
An anti-HIV confirmed serological positive result on the first sample, with one of the 
following subsequent tests on a separate second sample: 
 - A serological anti-HIV positive result. 
- A significant viral load result, where a detectable quantity of HIV nucleic acid is reported. 
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Appendix 2:  Current HIV Surveillance form, 2014 
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Appendix 3: Data completeness only where forms are returned (n=622), 2012 and 2013 
(cells with less than 80% are highlighted in red) 
Section Question Number with 
information 
completed 
% of total cases 
with information 
completed 
Patient Details DOB 622 100.0 
Sex 622 100.0 
County of residence 622 100.0 
Date of diagnosis 620 99.7 
Country of Birth 600 96.5 
Ethnicity 505 81.2 
Probable Country of Infection 469 75.4 
Sexual Orientation 594 95.5 
Pregnant (% of females) 143 85.1 
Gestational age (% of those pregnant) 22 66.7 
Reason for test 564 90.7 
Probable route 
of HIV infection 
Probable route of transmission 609 97.9 
> Hetero subcategory (of 257 hetero cases) 207 80.5 
> Duration of drug use (of 28 PWID) 17 60.7 
Laboratory 
information 
CD4 count at diagnosis 566 91.0 
CD4 % at diagnosis 472 75.9 
Viral load at diagnosis 494 79.4 
Date of initial NVRL test 545 87.6 
HIV type 617 99.2 
P24 antigen
1
 27 na 
Testing history Previously tested positive for HIV  526 84.6 
> Country of test (of 131 who previously tested positive) 122 93.1 
> Year of test (of 131 who previously tested positive) 113 86.3 
Previously tested negative for HIV 428 68.8 
> Country of test (of 250 who previously tested negative) 230 92.0 
> Year of test (of 179 who previously tested negative) 232 92.8 
Co-infections Co-infected with syphilis 577 92.8 
Co-infected with chlamydia 560 90.0 
Co-infected with gonorrhoea 562 90.4 
Co-infected with hepatitis B 588 94.5 
> Stage of hepatitis B infection (of 33 co-infected with hepB) 17 51.5 
Co-Infected with hepatitis C 582 93.6 
> Stage of hepatitis C infection (of 54 co-infected with hepC) 12 22.2 
Clinical Stage 
and AIDS 
Clinical Stage  586 94.2 
> Date of AIDS diagnosis (of 62 with AIDS) 50 80.6 
> AIDS-defining illness (of 62 with AIDS) 60 96.8 
ART indicated 463 74.4 
ART initiated 450 72.3 
> Date ART initiated (of 230 where ART was initiated) 201 87.4 
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Appendix 4:  Overview of the current and revised set of variables for HIV/AIDS 
surveillance 
 
Current European HIV dataset Proposed European HIV dataset (pilot) 
Common set of variables TESSy System Related Variables 
1. RecordID 1. RecordID 
2. RecordType  2. RecordType  
3. RecordTypeVersion  3. RecordTypeVersion  
4. Subject  4. Subject  
5. Status  5. Status  
6. DataSource  6. DataSource  
7. ReportingCountry 7. ReportingCountry 
8. DateUsedForStatistics 8. DateUsedForStatistics 
9. Age Diagnosis Information 
10. Gender 9. DateOfDiagnosis 
11. Outcome 10. DateOfNotification 
12. DateOfOnset 11. HIVType 
13. DateOfDiagnosis 12. Transmission 
14. DateOfNotification 13. TransmissionPartner 
15. Classification 14. ProbableCountryOfInfection 
16. ClinicalCriteria 15. FirstCD4Count 
17. LaboratoryResult 16. FirstCD4Date 
18. EpiLinked 17. RecentInfectionAssay 
 18. RecentInfectionScore 
 19. RecentInfectionSampleDate 
Disease Specific Variables Demographics 
19. HIVType 21. Age 
20. Stage 22. Gender 
21. Transmission 23. CountryOfBirth 
22. TransmissionHetero 24. YearOfArrival 
23. TransmissionMTCT 25. LastAttendanceDate 
24. HIVStatus Clinical Information 
25. DateOfAIDSDiagnosis 26. ART 
26. DateOfDeath 27. CD4Latest 
27. CountryOfBirth 28. CD4LatestDate 
28. CountryOfNationality 29. VLLatest 
29. RegionOfOrigin 30. VLLatestDate 
30. CD4Cells 31. DateOfAIDSDiagnosis 
31. ProbableCountryOfInfection 32. AIDSIndicatorDisease 
 Death 
 33. DateOfDeath 
 34. DeathCause 
 
 
 
